Industries > Pharma > Pharma ADMET Testing: World Industry and Market Prospects 2015-2025
Pharma ADMET Testing: World Industry and Market Prospects 2015-2025
ADMET Products and Services – Your Guide to Trends and Revenue Potentials
The pharma ADMET testing market gains much interest from pharmaceutical companies as they look to implement more-predictive ADMET testing. That finding and many others appear in a new report by Visiongain.
Absorption, distribution, metabolism, excretion and toxicology (ADMET) testing is an integral part of drug development. Visiongain estimates the ADMET testing market was valued at $5.80bn in 2014, with the majority of revenues being attributed to in vitro testing.
Our new report gives you 51 tables, 48 charts and three interviews. Discover the most lucrative areas in that industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions for those pharma R&D technologies. There is much opportunity in that fast moving market.
Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments. Commercial drivers and restraints for each submarket are also provided, as are revenue forecasts to 2025.
• In vitro ADMET testing
• In vivo ADMET applications
• In silico ADMET uses.
Our new study predicts the pharma ADMET testing market will expand throughout the forecast period, 2015 to 2025, driven by increased demand for that screening and advances in technology enhancing the reliability and predictive capabilities of those assays.
Leading companies and potential for market growth
Overall revenue for the pharma ADMET testing market will reach $10.51bn in 2019, our work forecasts. We predict strong revenue growth through to 2025, as drug developers select stronger product candidates for development, using ADMET technology.
Our work also analyses prominent companies in that market. See Visiongain’s analysis of leading companies, including these:
• Agilent Technologies
• Bio-Rad Laboratories
• Charles River Laboratories
• WuXi PharmaTech
• Promega Corporation
A company profile gives you the following information where available:
• Recent historical revenues
• Discussion of a company’s activities, technologies and outlook
• Brief assessment of the company’s ADMET strategy.
With that information you will assess competitors’ capabilities, progress, and commercial prospects, helping you stay ahead and benefit your reputation for insight.
National markets for those drug development technologies
Our study shows you prospects for ADMET sales in developed and developing countries. You will see individual revenue forecasts to 2025 for 12 countries:
• United States
• Germany, France, United Kingdom, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC)
• South Korea.
With our analysis you will investigate regions with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.
What forces affect the pharma ADMET testing industry?
Our new report discusses issues and events affecting the pharmaceutical ADMET testing
industry and market. You will find discussions, including qualitative analyses:
• Rising demand for early ADMET testing
• Developments in that drug screening technology.
You will see discussions of technological, commercial, and economic issues, with emphasis on the competitive landscape and business outlooks. Discover what the future holds.
How Pharma ADMET Testing: World Industry and Market Prospects 2015-2025 helps
In particular, our new investigation gives the following knowledge to benefit your work:
• Revenue forecasts to 2025 for the pharma ADMET testing market – discover that industry’s commercial prospects, finding what revenues and growth are possible
• Revenue forecasts to 2025 for three submarkets – explore sales potentials of in vitro, in vivo and in silico testing
• Revenue forecasts to 2025 for 12 leading national markets – US, EU5 (Germany, France, UK, Italy and Spain), Japan, Brazil, Russia, India, China and South Korea
• Assessment of leading companies – assess competitors, exploring their product and service portfolios, strategic developments and commercial outlooks
• Exclusive interviews with three companies – gain opinions from MultiCASE Inc., Optivia Biotechnology and Takara Bio Europe AB, seeing what participants say and do
• Discussion of what stimulates and restrains companies and the market – examine forces affecting those technologies and their providers
• Prospects for established firms and those seeking to enter the industry – discover what the future holds, helping you stay ahead in knowledge.
There you will find quantitative and qualitative analyses with independent predictions. That way you will receive information that only our report contains, staying informed on business intelligence.
Data and discussions found nowhere else, helping your research, analyses and decisions
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s new study is for everybody needing analyses of the pharma ADMET testing market and that industry’s leading companies. There you will find data, trends and predictions. Stay ahead by getting that report here now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6